+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of expression and correlation between P53, BCL-2 and BAX proteins in ovarian neoplasms



Evaluation of expression and correlation between P53, BCL-2 and BAX proteins in ovarian neoplasms



Ginekologia Polska 73(2): 102-109



Interactions between BCL-2 and other proteins regulating programmed cells death in ovarian carcinomas are poorly understood. The evaluation of expression of P53, BCL-2 and BAX proteins in ovarian carcinomas. The associations between oncoproteins studied and the histological structure, grade of differentiation and stage of disease were also analysed. The expression of P53, BCL-2 and BAX was evaluated by immunoperoxidase technique (PAP) in tissue sections and corresponding cyst and/or ascitic fluid cells in individual patients with ovarian carcinoma. It was shown that the expression of P53 and BAX was comparable in tissue sections and cyst or ascitic fluid cells of individual patients, however the presence of BCL-2 was detected more frequently in tissue sections. No correlations between markers studied and histological subtypes and grade of carcinoma were found. Taking into account the relationship between P53, BCL-2 and BAX expression, it was possible to classify the studied ovarian carcinomas into four phenotypes. Ovarian cancers with phenotype P53+/BCL-2- were more frequent in III/IV degree FIGO stages whereas the phenotype P53-/BCL-2+ were identified mainly in patients in I/II degree FIGO stages. The progression of disease and death occurred more frequently in groups with phenotype P53+/BCL-2+ and P53-/BCL-2-. Our observations indicated that estimation of P53, BCL-2 and BAX protein expression may be important in the choice of the chemotherapy.

(PDF emailed within 1 workday: $29.90)

Accession: 046009705

Download citation: RISBibTeXText

PMID: 12001767


Related references

Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology. American Journal of Clinical Pathology 105(3): 334-340, 1996

Abnormal expression of the retinoblastoma gene in ovarian neoplasms and correlation to p53 and K-ras mutations. Gynecologic Oncology 58(3): 307-311, 1995

The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables. Journal of Molecular Histology 45(6): 679-687, 2015

Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. Journal of the Egyptian National Cancer Institute 17(3): 173-183, 2006

Expression of c-kit and stem cell factor in primary ovarian neoplasms Correlation of c-kit with carcinomas vs tumors of low malignant potential. Laboratory Investigation 81(1): 141A, January, 2001

Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. American Journal of Surgical Pathology 29(3): 281-294, 2005

The immunohistochemical expression of proliferating cell nuclear antigen (PCNA/cyclin) in malignant and benign epithelial ovarian neoplasms and correlation with prognosis. European Journal of Cancer 29A(11): 1599-1601, 1993

An evaluation of CA125, CA1 and peanut lectin immunoreactivity in epithelial ovarian neoplasms: correlation with histopathological features, prognostic variables and patient outcome. Pathology 20(1): 38-44, 1988

Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. International Journal of Gynecological Cancer 19(8): 1322-1328, 2010

Evaluation of Preoperative Serum Levels of CA 125 and Expression of p53 in Ovarian Neoplasms: A Prospective Clinicopathological Study in a Tertiary Care Hospital. Journal of Obstetrics and Gynaecology of India 66(2): 107-114, 2016

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. British Journal of Cancer 76(9): 1221-1227, 1997

Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer. International Journal of Oncology 43(2): 513-520, 2014

CD44 standard form expression in ovarian neoplasms and benign ovarian epithelium. Modern Pathology 12(1): 123A, 1999

Immunohistochemical evaluation of expression of heat shock proteins HSP70 and HSP90 in mammary gland neoplasms in bitches. Polish Journal of Veterinary Sciences 15(2): 209-214, 2012